Core Viewpoint - The company is actively monitoring the competitive landscape of generic drugs under the normalized centralized procurement and is advancing its R&D projects in various therapeutic areas including cancer, kidney disease, diabetes, and cardiovascular diseases [2] Group 1: R&D Strategy - The company is focusing on the development of new products and the secondary development of major varieties to enhance its R&D capabilities [2] - It is strategically investing in drug development across multiple therapeutic fields [2] Group 2: Financial Strategy - The company is leveraging a dual-driven model of "pharmaceutical health + financial capital" to reinvest financial returns into its pharmaceutical core business [2] - It plans to reasonably allocate R&D investments based on actual development needs to steadily advance its R&D efforts [2] Group 3: Market Positioning - The company is positioning itself to improve its core competitiveness in the pharmaceutical industry through continuous R&D advancements [2]

Group 1 - The core viewpoint of the article is that Jilin Aodong anticipates significant growth in its 2025 performance due to increases in fair value changes and investment income [2] - The company stated that its main business operations are stable and the overall fundamentals have not undergone significant changes [2]

Group 1 - The company is closely monitoring the normalization of centralized procurement in the pharmaceutical industry and the trends in innovative drug development [2] - The company is focusing on its core pharmaceutical business and continuously promoting product innovation and research and development [2] - The company plans to leverage its advantages across the entire pharmaceutical industry chain to strategically manage R&D investments and carefully assess the direction and pace of innovative drug development [2]

Group 1 - Jilin Aodong's stock price has dropped 0.05% to 18.87 CNY per share, with a total market capitalization of 22.567 billion CNY and a trading volume of 422 million CNY, reflecting a turnover rate of 1.88% [1] - The stock has experienced a cumulative decline of 9.24% over the past three days [1] - Jilin Aodong Pharmaceutical Group Co., Ltd. was established on March 20, 1993, and listed on October 28, 1996, focusing on traditional Chinese medicine, biochemical drug R&D, manufacturing, and sales, with additional ventures in health foods, food, breeding, and planting [1] Group 2 - The main revenue composition of Jilin Aodong includes traditional Chinese medicine (60.90%), wholesale and retail of chain pharmacies (16.59%), chemical drugs (12.73%), food (7.39%), and other products (1.76%) [1] - Hongde Fund has one fund heavily invested in Jilin Aodong, with Hongde Hongye Mixed Fund (001695) holding 22,900 shares, accounting for 0.58% of the fund's net value, ranking as the ninth largest holding [2] - The fund has incurred a floating loss of approximately 229 CNY today and a total floating loss of 44,000 CNY during the three-day decline [2]

Core Viewpoint - The company adheres to a "pharmaceutical health + financial capital" dual-driven strategy, leveraging its deep pharmaceutical industry foundation and mature product matrix to maintain strong market competitiveness [1] Group 1: Company Strategy - The company emphasizes the importance of its dual-driven strategy for sustainable development, integrating pharmaceutical and financial sectors [1] - Financial investment activities are designed to support the development of the pharmaceutical industry, with investment returns primarily allocated to research, production, and upgrading of the industrial chain [1] Group 2: Future Outlook - The company aims to continue deepening the synergy between production and finance, striving for stable performance to reward investors [1]

Core Viewpoint - The recent performance of the Chinese medicine sector, particularly the Chinese Medicine ETF (560080), indicates a potential shift in investment style, with increasing capital inflow and favorable valuation metrics suggesting a recovery phase ahead for the industry [3][8]. Group 1: Market Performance - On February 2, the Shanghai Composite Index fell by 2.48%, while the Chinese Medicine ETF (560080) experienced a decline of 1.24%, with a total trading volume exceeding 70 million yuan [1]. - The Chinese Medicine ETF has seen continuous capital inflow, accumulating over 100 million yuan in net inflow over the past five days [1][3]. Group 2: Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the Chinese Medicine ETF is 23.96, indicating that the valuation is below 85.61% of the time since its inception in May 2015, highlighting attractive valuation opportunities [3]. - The Chinese medicine sector is perceived to be entering a "sweet spot" in terms of valuation, with a significant portion of stocks showing potential for recovery [3]. Group 3: Individual Stock Performance - Most of the weighted stocks in the Chinese Medicine ETF index closed lower, with notable declines including Jilin Aodong down over 7% and Darentang down over 3% [5]. - Conversely, Dong'e Ejiao was one of the few stocks that rose, gaining over 1% [5]. Group 4: Earnings Forecasts - Jilin Aodong has projected a net profit of approximately 2.265 to 2.482 billion yuan for 2025, representing a year-on-year growth of 46.0% to 60.0%, attributed to increased fair value changes and investment income [7]. - As of January 31, 11 companies within the Chinese Medicine ETF index have released earnings forecasts, with six reporting positive year-on-year growth [7]. Group 5: Future Outlook - The Chinese medicine sector is expected to experience a rebound in 2026, driven by inventory digestion and an anticipated increase in flu incidence in Q4 2025, which may enhance sales of related OTC products [8]. - The potential update of the essential drug catalog is also seen as a catalyst for growth, with companies that can meet the new criteria likely to benefit [8]. Group 6: Investment Themes - Three main investment themes have been identified for the Chinese medicine industry: price governance, consumption recovery, and state-owned enterprise reform [9][10][11]. - The focus on price governance suggests that companies with competitive advantages may benefit from price reductions leading to increased market share [9]. - The recovery of consumer demand, driven by macroeconomic improvement and an aging population, is expected to support sales growth in the Chinese medicine sector [10]. - State-owned enterprises in the industry are anticipated to present investment opportunities as reforms aim to enhance efficiency and performance [11].

Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]

Group 1 - Jilin Aodong Pharmaceutical Group Co., Ltd. experienced a decline of 5.09% in stock price, reaching 19.40 CNY per share, with a trading volume of 518 million CNY and a turnover rate of 2.22%, resulting in a total market capitalization of 23.2 billion CNY [1] - The company, established on March 20, 1993, and listed on October 28, 1996, is primarily engaged in the research, development, manufacturing, and sales of traditional Chinese medicine and biochemical drugs, while also expanding into health food, food, breeding, and planting sectors [1] - The revenue composition of Jilin Aodong includes traditional Chinese medicine at 60.90%, wholesale and retail of chain pharmacies at 16.59%, chemical drugs at 12.73%, food at 7.39%, other products at 1.76%, and additional income at 0.62% [1] Group 2 - From the perspective of fund holdings, one fund under China Merchants Asset Management has Jilin Aodong as its second-largest holding, with 17,900 shares, accounting for 2.52% of the fund's net value, resulting in an estimated floating loss of approximately 18,600 CNY today [2] - The fund, China Merchants CSI 500 Index Enhanced Initiation A (023192), was established on January 16, 2025, with a latest scale of 13.4258 million CNY, and has achieved a year-to-date return of 10.94%, ranking 999 out of 5,579 in its category [2] - Over the past year, the fund has generated a return of 48.38%, ranking 1,410 out of 4,285 in its category, and since inception, it has achieved a return of 48.02% [2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：自愿性业绩预告 （1）以区间数进行业绩预告的 单位：万元 二、与会计师事务所沟通情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:000623 证券简称:吉林敖东 公告编号:2026-001 公司已就业绩预告有关事项与会计师事务所进行了预沟通，公司与会计师事务所在业绩预告方面不存在 分歧。本次业绩预告未经过注册会计师预审计。 三、业绩变动原因说明 报告期内，公司围绕市值管理，聚焦医药主业，持续提升经营质量，积极践行"专注于人、专精于药"的 企业价值观，实施"大品种群、多品种群"的销售拉动政策，坚持走"医药健康+金融资本"双轮驱动快速 发展的道路，按照年初制定的估值提升计划有序推进各项工作，业绩取得大幅增长主要原因是公司公允 价值变动收益及投资收益同比增加。 2025年，预计非经常性损益金额对净利润的影响金额约为19,568.93万元（2024年同期为-2,151.12万 元）。 四、风险提示 1 ...

证券日报网讯 1月30日，吉林敖东发布公告称，公司预计2025年度归属于上市公司股东的净利润为 226503.39万元至248222.90万元，比上年同期增长46.00%至60.00%。 （编辑 丛可心） ...